Paris, France / Rome, Italy, September 29, 2022 – Chronolife, a pioneering digital health service operator and MedTech company specializing in the remote, continuous, and multi-parametric monitoring of patients and persons at risk in real life conditions through healthcare certified smart textile, announced today a collaboration with Garmin, a leading global provider of fitness smartwatches and GPS-enabled products, during the annual Global Garmin Health Summit in Rome, Italy.
The collaboration will offer comprehensive remote patient monitoring services, operated by Chronolife in Europe and in the United States, through the collection of complementary key medical and physiological data generated by Garmin1 and Chronolife’s respective wearables in real life conditions and integrated into Chronolife’s service platform, bringing more precision for follow-ups of pathologies and disorders as well as diagnosis and risk assessments.
Chronolife’s ecosystem of digital health services’ interoperability attribute allows the secured integration of Chronolife’s proprietary medical devices as well as third party devices used by at-risk patients and persons in its service platforms operated in Europe and in the United States. On top of delivering the raw physiological data, the platforms provide healthcare
indicators supporting early detection of deteriorating health conditions outside the hospital and in real life conditions to its customers (hospitals, pharma, home care service providers, insurers, etc.).
Physiological and fitness data collected by Garmin wearables, such as smartwatches, will automatically be integrated into Chronolife’s medical data hub, without the need for the patients or persons at risk to handle multiple applications.
Chronolife’s Keesense™ service suite, prescribed today by healthcare professionals for the remote monitoring of patients with chronic heart failures, respiratory diseases, long COVID and in oncology, will therefore be enriched thanks to the integration of Garmin wearables and data. Chronolife’s Keesense healthcare certified t-shirt and associated smartphone application collecting continuously several physiological parameters (cardio frequency through a single lead ECG, the thoracic respiration, the abdominal respiration, the pulmonary impedance, the temperature of the body and the activity) and delivering to Chronolife’s customers with healthcare indicators such as Heart Rate Variability (HRV), Apnea detection, extrasystole detection (…), will be complemented by the automatic collection of sleep, stress, and Pulse Ox2 data through the Garmin wearables.
Thanks to the devices’ simplicity of use and comfort blending seamlessly into users’ everyday life whatever its activity and style of life, patients’ adherence to the healthcare protocol is improved. Healthcare professionals are provided with the suite of reliable, continuous, and precise physiological data and healthcare indicators they need to track the evolution of the health and pathologies of the patients thus supporting the Continuum of Care in and outside the hospital. Consequently, the quality of life of the patients remotely monitored can be improved.
“We are thrilled to collaborate with a leading manufacturer such as Garmin. Garmin wearables provide precious high quality sensor data and fit perfectly in patients’ daily lives, in line with our aim to contribute to the provision of higher value care to patients, reduce avoidable hospitalization, and eventually improve population health in a context of overburdened healthcare systems worldwide,” said Laurent Vandebrouck, CEO of Chronolife.
Jörn Watzke, Senior Director at Garmin Health, said: “We see a lot of potential in the integration of Garmin wearables into Chronolife’s cutting-edge medical data hub. Through this strategic alliance, more use cases for remote patient monitoring in daily life operated by Chronolife can be covered.”
The integration will improve offering for remote patient monitoring, clinical trials, therapeutic efficiency, and preventive care programs of Chronolife’s customers, from hospitals to pharmaceutical or insurance companies, which require end-to-end
certified connected health services.
“It will also allow us to deliver a complete follow-up for a large scope of additional use cases, such as people suffering from sleep disorders, for sportsmen in reathletization, for operators in the field of defense, and finally for elderlypeople within the framework of home care,” added Vandebrouck.
About Chronolife – Real time intelligence for healthcare
Chronolife operates an open ecosystem of digital health turnkey services for remote patient monitoring and early detection of deteriorating health conditions. The company relies on its own off-the-shelf or custom multiparametric connected medical devices as well as 3rd-party devices for continuous monitoring of everyday life. Chronolife valorizes and makes the data available through telemonitoring platforms. Founded in 2015 and based in Paris, with a subsidiary in San Diego, Chronolife
was co-founded by iBionext, a unique ecosystem and investment fund dedicated to the creation of innovative healthtech startups.
For more information: join us on LinkedIn or visit us at https://chronolife.net.
Vae Solis Communications
+33 (0)1 53 92 80 00
Cancer treatment is typically an arduous, long process for patients who often suffer from painful side effects as well as emotional duress, not to mention the psychological burden that comes with having to stay in physically-confining spaces in order to receive constant health monitoring. To improve patient wellbeing and manage symptom exacerbations, health systems are getting more and more innovative with how they manage cancer patients.
Chronolife has created Keesense, a connected t-shirt and medical device that continuously monitors multiparameter physiological data, to help healthcare professionals remotely assess patients’ health status throughout the care continuum. In this 3-weeks clinical investigation, young adults and elderly cancer patients who are undergoing antineoplastic treatment at Rigshospitalet will wear Keesense for 12 hours a day. Patients will be equipped with a smartphone accompanying app to retrieve their physiological data and to monitor the rate and quantity of data transmission compared with actual patient activity logs.
Participating patients will be observed for their adherence, comfort level and experience with the Keesense medical device, which is worn just like any other regular daily undergarment and designed to allow complete freedom of movement. The aim is to transform the cancer patient experience by giving patients the independence and freedom they crave in a normal life which will help address treatment-related depressions and boost their positivity levels.
“I’m excited to see Keesense’s new use case in cancer patient management, to demonstrate its benefits in enhancing the oncology patient’s care pathway,” said Laurent Vandebrouck, CEO of Chronolife. “We’re honored to collaborate with such a forward-thinking health center as Rigshospitalet that is looking to transform oncology care with next-gen technology while also improving patient quality of life.”
At the completion of the clinical investigation, Chronolife and Rigshospitalet will collaborate on authoring scientific papers based on the analysis and reporting of study results and outcomes to contribute in academic publications. This could provide meaningful guidance for oncology physicians and healthcare providers as they navigate remote monitoring programs for early intervention in cancer patients such as prescribing supportive medications, making dosage modifications, and providing targeted patient education materials.
Chronolife operates an open ecosystem of digital health turnkey services for remote patient monitoring and early detection of deteriorating health conditions. The company relies on its own off-the-shelf or custom multiparametric connected medical devices as well as 3rd-party devices for continuous monitoring of everyday life. Chronolife valorizes and makes the data available through telemonitoring platforms. Founded in 2015 and based in Paris, with a subsidiary in San Diego, Chronolife was co-founded by iBionext, a unique ecosystem and investment fund dedicated to the creation of innovative healthtech startups.
USA: Ran Xu – Rosebud
Helle Pappot – Clinical Professor
The Keesense solution, manufactured by Chronolife, is intended for the continuous monitoring of physiological parameters. This medical device is a regulated health product which is CE marked under this regulation. Please read the instructions for use carefully. March 2022.
The agreement covers the development and integration of sensors and electronic components for the collection of physiological and environmental data in equipment intended for Civil Security, particularly for firefighters, to prevent thermal stress, alert the wearer and thus improve his/her safety.
The aim of this contract is, beyond this first application, to offer the solution to individuals working in high-risk environments in fields such as Defense, industries, in France, where contacts with the Ministry of Armed Forces and the Ministry of Interior are underway, and abroad, mainly in Europe and the United States.
For Jean-Pol Kahn, Managing Director of Europrotect: « Chronolife’s patented, proven and health-certified technologies will allow the collection of physiological data in hostile environments. In addition, they perfectly fit with the reliability and ergonomics requirements of firefighters, to not hinder their mobility. We look forward to assessing their performances in real-life conditions. »
« We are proud that Europrotect chose Chronolife and its patented, health-certified technologies and physiological data sensors to equip its technical textiles for extreme conditions use. This will enable us to provide a very high level of risk monitoring for firefighters in theaters of operation. », says Laurent Vandebrouck, CEO of Chronolife. « This is an inspiring use case for our Reference Design offering, leveraging our technologies implemented in connected health and remote monitoring for professionals exposed to and working in high-risk environments. »
Chronolife provides an open ecosystem of turnkey digital health services for remote patient monitoring, early symptom detection, and anticipation of health deterioration. The company relies on its own off-the-shelf multiparametric connected medical devices as well as on third-party devices for continuous monitoring. Chronolife valorizes and delivers the data via remote monitoring platforms. Founded in 2015 and based in Paris (France), with a subsidiary in San Diego (USA), Chronolife was co-founded by iBionext, a unique ecosystem and investment fund dedicated to the creation, development, and funding of innovative start-ups in health technologies, and majority shareholder of Chronolife since its creation.
EUROPROTECT is a major actor in the field of technical textiles for human protection in Europe. It is one of the few manufacturers of technical textiles to be involved from weaving to finishing/printing. This strength allows them to control the production process from manufacturing to commercialization of products. EUROPROTECT offers customized products and services and provides its expertise thanks to its knowledge of the manufacturing process and its Research and Development department with over 30 years of experience. EUROPROTECT’s activity covers all Europe, Maghreb, Asia, and South America.
For more information: http://www.epf-ex.com/
Soizic Fleury – Marketing Director
Press relation Chronolife
Annie-Florence Loyer – NewCap
+33 (6) 88 20 35 59
Juliette Milleret – NewCap
Juliette DUPRIEZ – Project Manager
Chronolife has developed a CE and FCC approved monitoring device, based on a connected wearable t-shirt that is capable of continuously tracking wearers’ health status for a comprehensive set of physiological parameters. Mission First Solutions chose to partner with Chronolife because its connected t-shirt is machine-washable and worn just like any other comfortable undergarment, allowing continuous and reliable remote monitoring of soldiers without being intrusive to their daily rigorous activities, from intense training to actual combat operations. Offered as part of an end-to-end solution offering, Chronolife is able to meet the strictest, military-grade requirements in the design and production of these smart t-shirts catered to the specific needs of different military units and departments.
Initially under this partnership, Chronolife and Mission First Solutions will co-develop custom solutions that tackle two key challenges facing the military:
“Mission First Solutions is thrilled to have Chronolife as a partner. The future of healthcare is remote monitoring capability outside of medical facilities, wearables and early detection, which is Chronolife’s expertise. The Chronolife technology will allow the defense health agency and the other government healthcare interests, to provide remote monitoring to anyone requiring it. Chronolife’s cutting edge technology and nimble adaptability creates a unique opportunity to change the way a person’s health is monitored and treated.”
“We’re excited to partner with government HIT leader Mission First Solutions in providing the highest level of tech-enabled care for U.S. soldiers, both on and off the battlefield, both mentally and physically,” said Laurent Vandebrouck, CEO of Chronolife. “It’s an exciting use case of our smart textile reference design offering and reinforces our mission in developing truly personalized health monitoring solutions that blend seamlessly into users’ flow of work and life.”
Chronolife offers connected medical devices to optimize remote patient monitoring and diagnosis. The company also designs and develops custom digital connected solutions tailored to our partner’s specific needs. Chronolife directly supplies medical and ambulatory healthcare institutions, and partners with experts in the digitalization of the healthcare pathway, in France and internationally. Founded in 2015 and based in Paris (France), with a presence in San Diego (USA), Chronolife was co-founded by iBionext, a unique ecosystem and investment fund dedicated to the creation, development and financing of innovative start-ups in the field of health technologies, and majority shareholder of Chronolife since its creation.
For more information: https://www.chronolife.net/
Mission First Solutions, LLC, a premier Value-Added Reseller based in Triangle, VA to the Department of Defense (DoD) with a focus in the Defense Health Agency (DHA) a division of the DoD. As a Small Minority Owned Business, we deliver exclusive sales opportunity guidance and government navigation with insight to the information technology and government healthcare roadmap for strategic enterprise opportunities. Mission First Solutions, LLC provides access to multiple divisions within the federal government providing our clients, both small and large, high-level opportunities. Mission First Solutions, LLC offers a broad range of customer engagement, comprehensive IT services, hardware, software, and staff augmentation. Mission First Solutions, LLC’s staff has decades of experience prime contractor, conducting procurements, staff augmentation, and leading teams to not only meet but exceed our customers’ expectations. Mission First Solutions, LLC is proud to have a diverse team of IT specialists that hold certifications from the industry’s leading manufacturers and organizations. The technical engineers and service professionals at Mission First Solutions, LLC prides itself on having an agile and highly responsive business network to support the most demanding project requirements.
Soizic Fleury – Marketing Director
Mission First Solutions, LLC
Haider Jebur, President & CEO
Initiated as part of the second season of the Digital Pharma Lab programme, the partnership between Chronolife and the Chugai Pharma France laboratory aims to develop a smart textile for “real-life” monitoring of the impact of chronic pathologies on patients’ articular health.
The purpose of this device is to enable remote assistance and diagnosis in order to promote the “continuum of care” between the hospital, the ambulatory and a patient’s home. If successful, real-time processing of qualified alerts will enable rapid and appropriate therapeutic decisions to be made in the event of significant variations in the state of patients’ joint health, with the aim to significantly improve their quality of life.
“We are very proud to support Chugai Pharma France in this ambitious project. It is a recognition of Chronolife’s expertise in the design and development of innovative connected medical devices, applicable to specific use cases. This project is a continuation of our Keesense™ solution, a multiparametric connected t-shirt, certified CE Class Ila, that provides remote monitoring for patients with chronic cardiac, respiratory pathologies or Covid patients.”, says Laurent Vandebrouck, CEO of Chronolife.
“It is with great enthusiasm and humility that we start this innovative project with Chronolife. With enthusiasm as we hope to be able to provide an innovative and concrete solution aiming at improving the follow-up and joint health of patients. With humility because this is an exploratory and experimental initiative and we cannot at this stage predict the results. Transforming an innovative idea into a concrete solution will be an exciting journey and perfectly reflects the pioneering spirit that drives us at Chugai Pharma France.” says Nicolas Henriot, President of Chugai Pharma France.
Chronolife designs and develops medical devices and customized digital connected health solutions to optimize diagnosis, monitoring and prediction of chronic pathologies. Chronolife directly supplies medical and ambulatory healthcare institutions, and partners with experts in the digitalization of the healthcare pathway, in France and internationally. Founded in 2015 and based in Paris (France), with a presence in San Diego (USA), Chronolife was co-founded by iBionext, a unique ecosystem and investment fund dedicated to the creation, development and financing of innovative start-ups in the field of health technologies, and majority shareholder of Chronolife since its creation.
For more information: https://www.chronolife.net/
Founded in 1925 in Tokyo, Chugai Pharmaceutical Co., Ltd is one of Japan’s leading biotechnology drug development and production laboratories.
Mission and Innovation:
Chugai’s slogan is ” Innovation all for the patients”.
Its mission is to develop innovative drugs in areas where the medical needs of patients and the scientific community are still insufficiently covered.
Since its creation, Chugai’s image has been strongly linked to innovation. With a significant percentage of its annual turnover invested in research and development, Chugai possesses a rich portfolio of high value-added molecules.
For more information: https://www.chugai.fr/
Soizic Fleury – Marketing Director
Press relation Chronolife
Annie-Florence Loyer – NewCap
+33 (6) 88 20 35 59
Chugai Pharma France
Maxime Santos – Innovation & Transformation leader
Press relation Chugai
Nathalie Leroy – Director of General Affairs and Compliance
Initiated within the framework of the ETAPES program, this partnership aims to answer the growing expectations of healthcare facilities and home hospitalization structures, in a under pressured sanitary context. It offers a complete medical platform, fully configurable and customizable, which combines KeesenseTM, Chronolife’s solution, with TMM Software’s apTelecare, remote medical monitoring platform, to process qualitative alerts in real time, leading to rapid and appropriate therapeutic decisions in the event of significant changes in patient’s health.
Chronolife deploys an offer adapted to the needs of healthcare professionals, either through its CE marked Class Ila medical device Keesense™ in the form of a connected, comfortable, and machine-washable t-shirt, allowing the continuous and simultaneous measurement of several physiological parameters (electrocardiogram, physical activity, thoracic and abdominal respiration, pulmonary impedance and temperature), or by developing a personalized and tailor-made solution for the collection and analysis of health data for the monitoring of specific pathologies by leveraging its patented sensor, electronic and algorithmic technologies in healthcare.
“We are delighted to collaborate with TMM Software, a recognized expert in the digitalization of the care pathway. The complementarity and combination of our two offers and very open technologies will allow us to optimize the at-home care of patients suffering from respiratory failure in a tense health context. Our goal is to reduce the impact of chronic pathologies on the healthcare system by promoting outpatient care while improving patients’ quality of life.” says Laurent Vandebrouck, Chief Executive Officer of Chronolife.
“With Chronolife’s high-performance medical devices combined with our apTelecare platform used by about 60 healthcare facilities, we have combined our expertise to offer a remote medical monitoring solution that will facilitate the work of healthcare professionals and improve the continuity of remote care for patients with chronic pathologies.” Sébastien Bourrat, TMM Software’s Sales Director.
Chronolife and TMM Software are starting this collaboration in France, before developing similar initiatives for several chronic pathologies internationally: for instance, with the Moroccan government where TMM Software is equipping the entire population for the monitoring of undesirable effects following the vaccination against the COVID.
The Keesense t-shirt is a CE marked Class IIa connected medical device that integrates multiple sensors for the continuous and simultaneous measurement of several physiological parameters – electrocardiogram, physical activity, thoracic and abdominal respiration, pulmonary impedance, and skin temperature. It will integrate a patented neuromorphic algorithm HOTS (Hierarchy Of event-based Time-Surfaces) that allows for continuous data fusion and analysis to characterize and predict acute events related to chronic pathologies. Designed to be a “second skin”, Keesense frees patients from the constraints of traditional chronic disease monitoring (use of medical devices such as blood pressure monitors, thermometers, scales, and often unnecessary hospitalizations). Fully machine washable, Keesense promotes patient adherence to the remote monitoring solution.
Chronolife designs and develops medical devices and personalized connected digital health solutions to optimize the prediction, diagnosis, and monitoring of chronic pathologies. Chronolife directly supplies medical and ambulatory healthcare institutions and collaborates with experts in the digitalization of the care pathway.
Founded in 2015 and based in Paris (France), Chronolife was co-founded by iBionext, a unique ecosystem and investment fund dedicated to the creation, development, and funding of innovative start-ups in the field of health technologies, and a majority shareholder of Chronolife since its creation.
More information: https://chronolife.net
TMM Software has been accompanying healthcare stakeholders and improving patient experience for over 11 years. As an innovation driver, TMM Software develops unique, innovative, secure, open, and collaborative software solutions.
TMM Software digitalizes the care pathway and is committed to helping healthcare institutions improve their patients’ experience. As an “innovation activator”, TMM Software improves its solutions by co-developing with business experts, and offers two main products:
More information: http://tmm-software.com/
Soizic Fleury – Marketing Director
Sébastien Bourrat – Sales Director
The aim of this partnership is to set up an industrial production plan for Chronolife’s smart textile-based wearable health devices, designed to continuously collect multiple physiological data, necessary for the remote monitoring of patients suffering from chronic pathologies. The medical-grade product allows detection of health deterioration incidents by securely transmitting patient vitals in real time on a dedicated medical platform, which enables therapeutic management adapted to each patient.
Chronolife relies on the expertise of Mulliez Flory, a leading French mid-cap company specialized in the manufacturing of professional and health clothing, to integrate into their medical textiles the complex electronic components – sensors, electronic card, radio interface, battery and conductive textile threads – necessary for the collection of health data. At the end of the prototyping phase, Mulliez-Flory will start the industrialization of Chronofile’s first medical grade t-shirts thanks to a class IIa certification set to release in the beginning of 2021. Intended to be worn “daily” to optimize compliance, the connected T-shirts are machine washable with no damage or interference to the entire electronic parts.
“This agreement with Mulliez-Flory symbolizes a new stage in the development of Chronolife, in other words the industrialization of our offers following the milestone of our first commercial contracts with key players in the European health sector. We have great ambitions to meet the growing demand for remote patient monitoring; for example, around 35% of patients discharged from hospital after a Covid-19 episode suffer from pulmonary and cardiovascular complications that require long-term monitoring. Our multi-parameter solutions are designed for comfortable everyday usage, thus making it possible to continuously monitor their state of health in an environment that is familiar to them which is their home,” says Laurent Vandebrouck, CEO of Chronolife.
Thanks to a committed research and development policy, Mulliez-Flory has developed unprecedented know-how in the design of smart textiles in order to give products the monitoring and prevention characteristics that generate reliable and useful data for health professionals.
“Mastering our entire value chain enables us to develop new techniques for integrating electronic components into textile products. We are already developing other connected solutions in the Healthcare field and we are therefore highly motivated to work together with Chronolife on their unique remote patient monitoring solutions. We are very proud of this partnership between a rapidly growing start-up and a company with almost 200 years of existence that invests and innovates to remain at the forefront of particular market segments with high added value,” adds Jacques Gindre, Chairman of the Mulliez-Flory Group.
Chronolife is a company specializing in digital health, that develops different solutions for remote monitoring and prediction of the health status of a patient: Customizable Solution (CE(EU & FCC (US) approved); Medical Monitoring Solution, Keesense™ (CE Class IIa (EU) & FDA clearance ongoing (US)); Predictive Solution (CE Class IIb ongoing (EU)). Chronolife has developed a comfortable and washable connected garment that integrates multiple sensors to monitor physiological data continuously. Its “predictive solution” integrates the patented neuromorphic algorithm HOTS (Hierarchy Of event-based Time-Surfaces) to conduct data fusion. HOTS is being developed to continuously analyze several data flows to detect changes in a patient’s health and to trigger alerts to healthcare professionals to predict acute pathological episodes.
Chronolife was co-founded in 2015 by iBionext, a unique ecosystem and investment fund dedicated to the creation, development and financing of disruptive health tech start-ups, and majority shareholder of Chronolife since its creation.
More information: https://chronolife.net
The family-owned Group, established in Maine et Loire since 1824, has now 270 employees in France.
It advises, designs and manufactures professional clothing for the employees of major private and public accounts covering all markets. It also supplies textile equipment for local authorities and hospitals.
Mulliez-Flory controls its entire value chain. From consulting, design, integrating eco-design, marketing, prototyping, industrialization, manufacturing and logistics, the Group offers all French professionals the recycling of their end-of-life clothing as well as connected solutions to ensure the well-being and safety of employees.
Highly committed to sustainable development, the group has been CSR 26001 certified since 2018. This certification naturally leads to innovation and the development of more eco-responsible products: taking into account the product’s life cycle, better managing collections, using new technologies to make clothing a preventive tool…
More information: https://www.mulliez-flory.fr/
Soizic Fleury – Marketing Director
Annie-Florence Loyer – NewCap
Mob. +33 6 88 20 35 59
Mob. +33 6 84 61 30 71
The marked CE Class IIa medical device developed by Chronolife named Keesense™ includes a connected T-shirt which provides continuous and simultaneous measurement of several physiological parameters (electrocardiogram, physical activity, thoracic and abdominal respiration, pulmonary impedance and body temperature). The device is machine washable, very comfortable and easy to use, and facilitates both its use and patient compliance for an efficient remote monitoring. The measurement of the various physiological parameters recorded by Keesense on the be-ys optified-self platform allows the data to be visualized, and to alert practitioners in the event of a significant variation in the patient’s state of health in order to proceed with appropriate treatment.
In a context of a health crisis during which hospital services have to put up with a lot of pressure and face a tremendous lack of beds and resources to manage patients with chronic diseases, telemonitoring appears as a real opportunity to reduce hospital admissions and readmissions, but also as a real opportunity to bring back to the hospital only previously diagnosed patients who are indeed in need of intensive care, and finally to improve the quality of life of patients.
“Collaborating with the be-ys optified-self platform recognized for its expertise in the processing of personal and confidential health data flows has a real symbolic. It means guaranteeing doctors continuous remote monitoring thanks to multi-parametrical medical data collected in real-life conditions, but it also means providing a better remote diagnosis of the patient’s state of health. Our ambition with Keesense is to reduce the impact of chronic diseases regarding the organization of the healthcare system. Notably by reducing the number of hospital admissions or readmissions, while at the same time improving the quality of life of patients with continuous monitoring at home.” stated Laurent Vandebrouck, CEO of Chronolife.
“We are very pleased to start this collaboration with Chronolife. With Chronolife’s Keesense medical device associated with our platform, we have combined our technological expertise to offer a remote medical monitoring solution that will both facilitate the work of healthcare professionals and improve the continuity of remote care for patients with chronic diseases.” stated Laurent Caredda, chairman of be-ys.
Chronolife and be-ys start their collaboration with the aim to deploy this remote monitoring solution to several hospitals and cardiology departments in France. The two digital health experts plan to develop similar initiatives in the field of therapeutic efficiency, prevention and other chronic diseases. Chronolife’s Keesense solution and be-ys’ optified-self medical telemonitoring platform are part of the French decree on telemonitoring: the “ETAPES program” short for “Telemedecine Experimentation for the Improvement of Health Care Paths” in French.
Chronolife is a company specializing in digital health, that develops different solutions for remote monitoring and prediction of the health status of a patient: Customizable Solution (CE(EU & FCC (US) approved); Medical Monitoring Solution, Keesense™ (CE Class Iia (EU) & FDA clearance ongoing (US)); Predictive Solution (CE Class IIb ongoing (EU)). Chronolife has developped a comfortable and washable connected garment that integrates multiple sensors to monitor physiological data continuously. Its Predictive Solution integrates the patented neuromorphic algorithm HOTS (Hierarchy Of event-based Time-Surfaces) to conduct data fusion. HOTS is being developed to analyze several data flows continuously to detect changes in a patient’s health and to trigger alerts to healthcare professionals to predict acute pathological episodes. Chronolife was co-founded in 2015 by iBionext, a unique ecosystem and investment fund dedicated to the creation, development and financing of disruptive health tech start-ups, and majority shareholder of Chronolife since its creation.
More information: https://chronolife.net
be-ys positions itself as a universal digital trust agent with its own HDS-certified data center. be-ys health Solutions France is the subsidiary of the be-ys group dedicated to digital healthcare solutions. be-ys health Solutions France designs omnichannel and multiservice healthcare platforms, combining digital and human support. The optified-self solution is used by hospitals in SaaS mode for remote medical monitoring of patients with heart failure or with implanted prostheses. This solution is structured around an electronic patient record, and it can be integrated into hospital IT systems if required. It enables management of multi-parametrical alerts, coordination of city-hospital care, and visualization of the data collected by the connected objects.
More information: https://www.optified-self.com/optifiedself.telesurveillance/
Annie-Florence Loyer – NewCap: +33 6 88 20 35 59
Agnès Gilbert: +33 6 84 61 30 71
Chairman: 04 73 74 58 90
Paris, (France) July 23rd, 2020 – As part of the Coalition Innovation Santé – Crise Sanitaire initiative, Chronolife and Servier are collaborating to accelerate the deployment of a non-invasive telemonitoring solution which aims to facilitate remote monitoring of chronic patients during the COVID-19 pandemic and enable healthcare professionals to provide better patient care.
During the Covid-19 pandemic, hospital bed occupancy rates in intensive care units were very high. As a result, usual monitoring of vulnerable patients with chronic diseases became more difficult and thus a major source of concern for healthcare professionals. To improve patient care, medical devices using trackers, blood pressure monitors, thermometers and scales are often used to improve disease management, allowing for better long-term monitoring, and reduced avoidable re-hospitalizations. However, their constraints often result in problems with patient compliance.
In order to help healthcare practitioners during these unprecedented times, Chronolife has developed a smart t-shirt integrating multiple sensors and a smartphone application for the remote monitoring of patients. This medical device marked CE Class IIa and named Keesense™, allows for the continuous monitoring of 6 physiological parameters (electrocardiogram, physical activity, abdominal and thoracic breathing, skin temperature, and pulmonary impedance to detect edemas). Chronolife expects to receive FDA clearance for its Keesense™ solution by year 2021, to commercialize the product in the US. The measurement of these parameters in association with the Be-Ys platform, can highlight significant changes in the patient’s overall health to medical providers. The comfortable and machine washable t-shirt is easy to use. An interface developed by Be-Ys and already deployed across several French hospital centers, allows healthcare professionals to access and interpret these physiological parameters so that they can make the appropriate therapeutic decisions.
“We are very proud to be selected by the Coalition Innovation Santé for the remote and at-home monitoring of patients with chronic diseases using our medical device certified connected t-shirt, which can monitor multiple vital parameters continuously. The comfortable and machine washable t-shirt, guarantees greater patient compliance with telemonitoring services and could contribute to a better quality of life,” stated Laurent Vandebrouck, CEO of Chronolife. “We are working on several chronic conditions and use-cases such as heart failure, sleep apnea as well as postoperative follow-up in order to bring to these patients the benefits of real world continuous remote monitoring.”
With its expertise in cardiology, Servier has decided to support Chronolife in the carrying out of an experiment on the remote monitoring of 40 patients with chronic heart failure. The aim is to determine whether the smart t-shirt provides useful information to medical practitioners during the Covid-19 pandemic as well as assess its use in regular clinical practice. This will also be the opportunity to use the t-shirt in a real-world setting and monitor patients enrolled in a hospital telemonitoring program.
“We are very happy to support Chronolife in deploying their medical device that contributes to improving the continuum of care for patients with chronic diseases and to help facilitate the work of healthcare professionals, especially in this time of crisis,” said Olivier Nosjean, Servier Research Scientific Director.
 Be-Ys is a company developing technological tools to manage digital identities and personal and confidential data flows. Their solution optified-self is used for medical telemonitoring by some hospitals This solution is interoperable with hospital IT systems and enables the visualization of data collected by IOT devices used for patient remote monitoring.
Chronolife was co-founded in 2015 by iBionext, a unique ecosystem and investment fund dedicated to the creation, development and financing of disruptive health tech start-ups, and majority shareholder of Chronolife since its creation. Chronolife is a company specializing in digital health, that develops different solutions for remote monitoring and prediction of the health status of a patient: Customizable Solution (CE (EU) & FCC (US) approved); Medical Monitoring Solution, Keesense™ (CE Class IIa (EU) & FDA clearance ongoing (US)) ; Predictive Solution (CE Class IIb ongoing (EU)). Chronolife has developed a comfortable and washable connected garment that integrates multiple sensors to monitor physiological data continuously. Its Predictive Solution integrates the patented neuromorphic algorithm HOTS (Hierarchy Of event-based Time-Surfaces) to conduct data fusion. HOTS is being developed to analyze several data flows continuously to detect changes in a patient’s health and to trigger alerts to healthcare professionals to predict acute pathological episodes.
More information: https://chronolife.net
David Wamsley: email@example.com – Tél. +1-415-259-9104
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, oncology and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. One hundred million patients are treated daily worldwide with Servier drugs.
More information: www.servier.com
Sonia Marques: firstname.lastname@example.org – Tél. +33 (0)1 55 72 40 21 / +33 (0)7 84 28 76 13
Jean-Clément Vergeau: email@example.com – Tél. +33 (0)1 55 72 46 16 / +33 (0)6 79 56 75 96
About Coalition Innovation Santé
The “Coalition Innovation Santé – Crise Sanitaire” was created under the leadership of France Biotech, France Digitale, MedTech in France and the biopharmaceutical company AstraZeneca, with the support of AP-HP, Bpifrance, EIT Health. Current coalition partners are Novartis, Sanofi, Servier, Ipsen, GSK, MSD, Roche, Pfizer France Astellas, Medtronic, UCB, Grünenthal, Lilly, Amgen, Takeda, Chugai, Novo Nordisk, BMS, Mylan, Norgine, bioMérieux, Expanscience, Kyowa Kirin, La Diffusion Technique Française, Altran, Amazon Web Services, LEEM, G5 Santé, LIR, Urgo, La Cooper, Vivalto Santé, Alcimed, CapDecisif, AFSSI (Association Française des Sociétés de Services and Innovation), SIDIV (Syndicate of Industry and In Vitro Diagnostics), SNITEM, PactePME, competitiveness clusters in health: Atlanpôle Biothérapies, Biovalley France, Clubster NSL, Eurobiomed, LyonBiopôle, Medicen Paris Region, Angels santé, HEC Santé, the French League against multiple sclerosis, all mobilized to provide patients with chronic diseases with solutions as quickly as possible. The platform is implemented by Digital Pharma Lab, the first independent PharmaTech accelerator in Europe.
More information: https//www.coalitioncovid.org
Paris, April 28, 2020 /PRNewswire/ — Chronolife, an artificial intelligence company specializing in digital health, today announced that it has secured Class IIa medical certification from the European Union for its groundbreaking medical-grade smart T-shirt, KeeSense™. The multi-sensor wearable device continuously monitors electrocardiography (ECG), thoracic respiration, abdominal respiration, skin temperature, thoracic impedance, and physical activity, enabling healthcare practitioners to remotely track vital clinical data about their patients. The platform’s receipt of a medical Conformité Européenne (CE) mark allows KeeSense™ to be marketed in the European Economic Area as a wearable medical device for healthcare purposes including remote monitoring of patients with chronic diseases and support for diagnostics.
The KeeSense™ T-shirt is designed for comfortable round-the-clock use, and is fully reusable and washable, mimicking similar daily use garments. The unique T-shirt transmits data to its paired smartphone app via Bluetooth, which then sends the data to a secure and certified server for live or time-delayed analysis by the wearer’s healthcare team. The platform’s multi-parametric medical data enables researchers and healthcare teams to develop meaningful insights into patients’ long-term health, while also allowing prompt responses to medical emergencies.
Besides providing healthcare practitioners with a powerful new way to follow their patients, Chronolife’s Remote Patient Monitoring (RPM) platform will also enable pharmaceutical and medtech researchers to leverage a rich new source of round-the-clock, real-world physiological data to run more robust and efficient therapeutic efficiency programs and clinical trials. KeeSense™ monitoring is intended to be unobtrusive and to blend seamlessly with daily life, which could greatly improve both quality of life of the patients and their adherence to RPM devices. Healthcare stakeholders would be able to remotely and continuously monitor patients under real-life conditions, which could contribute to increased efficiency and improved outcomes of the RPM services.
“KeeSense™ delivers an unrivalled stream of real-world medical-grade data. This medical CE mark enables doctors to use KeeSense™ to provide more convenient and effective medical care, and gives researchers access to a rich new source of vital signs intelligence,” said Laurent Vandebrouck, CEO of Chronolife.
Chronolife also recently announced the launch of a major, pan-European clinical trial of a predictive solution using KeeSense™ to provide early warning of cardiac emergencies in patients with chronic heart failure. Researchers at 25 hospitals across Europe will collect KeeSense™ data to develop and validate the ability of Chronolife’s predictive HOTS algorithm to accurately alert healthcare providers of clinically significant events that signal deterioration in their patients’ conditions.
With KeeSense’s medical certification, Chronolife is now well-positioned for partnerships with a wide range of telemedicine services and telehealth providers to innovate and deliver end-to-end, continuous RPM programs. This will not only improve outcomes for patients with conditions that require constant monitoring, such as cardiovascular dysfunctions and respiratory illnesses, but also reduce hospital (re)admissions and help alleviate the ongoing shortage of healthcare resources and staff.
Co-founded with iBionext, Chronolife is an artificial intelligence company specializing in digital health. Its patented technology is a unique neuromorphic algorithm called HOTS (Hierarchy Of event-based Time Surfaces), which analyzes several data flows continuously, to characterize clinical events. Chronolife has developed a smart wearable that integrates various sensors to monitor physiological data continuously. This data is analyzed by the smartphone application on a patient’s phone that uses HOTS technology to conduct data fusion. It is capable of detecting changes in a patient’s health and triggering alerts to healthcare professionals to predict acute pathological episodes.